Previous studies have found that patients with disease progression experienced less worsening in HRQoL and lung cancer symptoms if treated with a PD‐(L)1 inhibitor compared to patients who received chemotherapy.12, 18. This evidence concerns the gene CD274 and lung carcinoma.